Radnostix, Inc. Reports FY2025 Results – Second-Highest Annual Revenue in Company History; Delivers Strong Growth in Calibration & Reference Products and Advances Key Product Launches in 2025

IDAHO FALLS, Idaho, April 1, 2026 /PRNewswire/ — Radnostix, Inc. (formerly International Isotopes Inc.) (OTCQB:INIS) (“Radnostix” or the “Company”), a leading manufacturer of radioisotope-focused technologies for medical, industrial, and research applications, today announced its fiscal year 2025 financial results and corporate updates.

Fiscal 2025 Highlights

• Total revenue reached $13.07 million, the second-highest annual revenue in Company history, reflecting healthy demand across core segments despite targeted supply chain challenges.
• Calibration & Reference Products segment achieved record growth, with sales increasing 21% to $4.25 million, driven by new PET-focused products, expanded international sales, and recovery from prior-year Co-57 isotope shortages.
• Theranostics Products segment generated $6.84 million in revenue, second-highest ever for the segment, despite multiple isotope shortages throughout the year. Our generic Sodium Iodide I-131 remains the only U.S.-manufactured generic of its kind.
• Cobalt Products segment delivered $1.75 million in revenue while successfully completing a major processing hot cell refurbishment that is expected to extend asset life by 15–20 years and reduce annual radiological waste costs by approximately $150,000. We are the only U.S.-based manufacturer of finished Cobalt-60 products.
• Medical Devices segment showed strong momentum with $229,000 in revenue from third-party products and key progress toward 2026 launches of the EasyFill Automated Capsule System and RadVent products.
• Positive operating cash flow of $620,000, underscoring disciplined cost management and operational efficiency despite raw material challenges.
• Completed construction and received initial NRC license amendment for a dedicated Calibration & Reference Products manufacturing facility, positioning the Company for significant capacity expansion and product portfolio growth in 2026.
• Executed mutual termination of the DUF6 asset sale agreement; Radnostix regained full control of these strategic assets amid the global nuclear energy boom and will evaluate development options, including potential license amendments for expanded uranium-related activities.

“2025 was a year of refinement for Radnostix, where we focused on internal improvements to, which we believe will set us up for long-term success. Despite isotope shortages and management decision to delay Q4 cobalt-60 projects to 2026, we delivered the second-highest revenue in our history while making substantial investments in our future. We completed critical facility upgrades, advancing our Medical Devices pipeline, and strengthening our position as a trusted domestic supplier of high-value radioisotope products.” Said Shahe Bagerdjian, President and Chief Executive Officer, adding “Our Calibration & Reference Products segment posted healthy growth, and we successfully refurbished our cobalt-60 hot cells, securing long-term production capability and cost savings. The name change to Radnostix implemented in Q4 of 2025 reflects our sharpened focus on innovation in advanced radioisotope technologies.”

“Looking ahead, we are excited about the anticipated 2026 commercial launches of EasyFill and RadVent, expanded international opportunities, and the strategic value of our retained DUF6 assets in today’s booming nuclear market.”

2026 Outlook
The Company enters 2026 with strong momentum and several key catalysts:

• Full commercial launch of the EasyFill Automated Capsule System (targeted Q3 2026) and RadVent products.
• Continued expansion of the Calibration & Reference Products facility and product line.
• Submitting a theranostics GMP API drug master file.
• Strategic evaluation of the DUF6 assets to capitalize on renewed global interest in uranium fuel cycle services.

Full story available on Benzinga.com